FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323923054> ?p ?o ?g. }

• W4323923054 endingPage "100499" @default.
• W4323923054 startingPage "100499" @default.
• W4323923054 abstract "Lorlatinib is a potent, third-generation inhibitor of ALK. In the planned interim analysis of the ongoing, phase 3, randomized, global CROWN trial (NCT03052608), lorlatinib resulted in significantly longer progression-free survival than crizotinib in patients with previously untreated, advanced, ALK-positive NSCLC. Here, we present a subgroup analysis of Asian patients in the CROWN study.Patients received lorlatinib 100 mg once daily or crizotinib 250 mg twice daily. The primary end point was progression-free survival assessed by blinded independent central review. Objective response rate (ORR), intracranial ORR, safety, and select biomarkers were secondary end points.At data cutoff (September 20, 2021), 120 patients were included in the Asian intention-to-treat subgroup (lorlatinib n = 59; crizotinib n = 61). At 36 months, 61% (95% confidence interval [CI]: 47-72) and 25% (95% CI: 12-41) of patients in the lorlatinib and crizotinib groups, respectively, were alive without disease progression (hazard ratio for disease progression by blinded independent central review or death: 0.40; 95% CI: 0.23-0.71). ORR was 78% (95% CI: 65-88) versus 57% (95% CI: 44-70) for patients treated with lorlatinib and crizotinib, respectively. In patients with measurable, nonmeasurable, or both measurable and nonmeasurable brain metastases at baseline, intracranial ORR was 73% (95% CI: 39-94) versus 20% (95% CI: 4-48) for patients treated with lorlatinib and crizotinib, respectively. The definition of nonmeasurable brain metastases is: a brain lesion less than 10 mm in MRI scan is defined as nonmeasurable brain metastasi based on RECIST criteria (Clinical trial evaluation criteria). Hypercholesterolemia, hypertriglyceridemia, and edema were the most frequently reported adverse events with lorlatinib.Lorlatinib efficacy and safety in the Asian subgroup of CROWN were consistent with those in the overall population." @default.
• W4323923054 created "2023-03-12" @default.
• W4323923054 creator A5001254402 @default.
• W4323923054 creator A5002500632 @default.
• W4323923054 creator A5004928583 @default.
• W4323923054 creator A5010034475 @default.
• W4323923054 creator A5016050402 @default.
• W4323923054 creator A5019037704 @default.
• W4323923054 creator A5020674154 @default.
• W4323923054 creator A5023105695 @default.
• W4323923054 creator A5028624269 @default.
• W4323923054 creator A5032293215 @default.
• W4323923054 creator A5033956905 @default.
• W4323923054 creator A5038101792 @default.
• W4323923054 creator A5046400988 @default.
• W4323923054 creator A5047490140 @default.
• W4323923054 creator A5056696568 @default.
• W4323923054 creator A5061691557 @default.
• W4323923054 creator A5062708568 @default.
• W4323923054 creator A5066717752 @default.
• W4323923054 creator A5069918600 @default.
• W4323923054 creator A5070808098 @default.
• W4323923054 creator A5073440860 @default.
• W4323923054 creator A5083634538 @default.
• W4323923054 date "2023-05-01" @default.
• W4323923054 modified "2023-10-18" @default.
• W4323923054 title "Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC" @default.
• W4323923054 cites W1964127544 @default.
• W4323923054 cites W2015436643 @default.
• W4323923054 cites W2031494655 @default.
• W4323923054 cites W2099530756 @default.
• W4323923054 cites W2115105291 @default.
• W4323923054 cites W2146016871 @default.
• W4323923054 cites W2163351155 @default.
• W4323923054 cites W2168106545 @default.
• W4323923054 cites W2482427906 @default.
• W4323923054 cites W2581996620 @default.
• W4323923054 cites W2589499669 @default.
• W4323923054 cites W2624310346 @default.
• W4323923054 cites W2767072667 @default.
• W4323923054 cites W2894476389 @default.
• W4323923054 cites W2899668190 @default.
• W4323923054 cites W2922836343 @default.
• W4323923054 cites W2923683745 @default.
• W4323923054 cites W3006257197 @default.
• W4323923054 cites W3024080307 @default.
• W4323923054 cites W3024551306 @default.
• W4323923054 cites W3028890726 @default.
• W4323923054 cites W3032595234 @default.
• W4323923054 cites W3043769118 @default.
• W4323923054 cites W3101089668 @default.
• W4323923054 cites W3147630494 @default.
• W4323923054 cites W4210992155 @default.
• W4323923054 cites W4282926341 @default.
• W4323923054 cites W4308432482 @default.
• W4323923054 doi "https://doi.org/10.1016/j.jtocrr.2023.100499" @default.
• W4323923054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37223611" @default.
• W4323923054 hasPublicationYear "2023" @default.
• W4323923054 type Work @default.
• W4323923054 citedByCount "1" @default.
• W4323923054 countsByYear W43239230542023 @default.
• W4323923054 crossrefType "journal-article" @default.
• W4323923054 hasAuthorship W4323923054A5001254402 @default.
• W4323923054 hasAuthorship W4323923054A5002500632 @default.
• W4323923054 hasAuthorship W4323923054A5004928583 @default.
• W4323923054 hasAuthorship W4323923054A5010034475 @default.
• W4323923054 hasAuthorship W4323923054A5016050402 @default.
• W4323923054 hasAuthorship W4323923054A5019037704 @default.
• W4323923054 hasAuthorship W4323923054A5020674154 @default.
• W4323923054 hasAuthorship W4323923054A5023105695 @default.
• W4323923054 hasAuthorship W4323923054A5028624269 @default.
• W4323923054 hasAuthorship W4323923054A5032293215 @default.
• W4323923054 hasAuthorship W4323923054A5033956905 @default.
• W4323923054 hasAuthorship W4323923054A5038101792 @default.
• W4323923054 hasAuthorship W4323923054A5046400988 @default.
• W4323923054 hasAuthorship W4323923054A5047490140 @default.
• W4323923054 hasAuthorship W4323923054A5056696568 @default.
• W4323923054 hasAuthorship W4323923054A5061691557 @default.
• W4323923054 hasAuthorship W4323923054A5062708568 @default.
• W4323923054 hasAuthorship W4323923054A5066717752 @default.
• W4323923054 hasAuthorship W4323923054A5069918600 @default.
• W4323923054 hasAuthorship W4323923054A5070808098 @default.
• W4323923054 hasAuthorship W4323923054A5073440860 @default.
• W4323923054 hasAuthorship W4323923054A5083634538 @default.
• W4323923054 hasBestOaLocation W43239230541 @default.
• W4323923054 hasConcept C126322002 @default.
• W4323923054 hasConcept C143998085 @default.
• W4323923054 hasConcept C168563851 @default.
• W4323923054 hasConcept C187960798 @default.
• W4323923054 hasConcept C203092338 @default.
• W4323923054 hasConcept C207103383 @default.
• W4323923054 hasConcept C2776232967 @default.
• W4323923054 hasConcept C2776256026 @default.
• W4323923054 hasConcept C2779422266 @default.
• W4323923054 hasConcept C2780739268 @default.
• W4323923054 hasConcept C3019894029 @default.
• W4323923054 hasConcept C44249647 @default.
• W4323923054 hasConcept C61943457 @default.

• next